Retraction Note to: Effect of alendronate on bone mineral density and bone turnovermarkers in post-gastrectomy osteoporotic patients (Journal of Bone and Mineral Metabolism, (2010), 28, 2, (202-208), 10.1007/s00774-009-0116-0);Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 2, 2010, Pages 202-208

  Iwamoto, Jun ^a   Uzawa, Mitsuyoshi ^b   Sato, Yoshihiro ^c   Takeda, Tsuyoshi ^a   Matsumoto, Hideo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Keiyu Orthopaedic Hospital   (Japan)

^c Mitate Hospital   (Japan)

Author keywords

Alendronate; Bone mineral density (BMD); Bone turnover; Gastrectomy; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; VITAMIN D; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; COLLAGEN; URINARY N TELOPEPTIDE OF TYPE I COLLAGEN, HUMAN; URINARY N-TELOPEPTIDE OF TYPE I COLLAGEN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GASTRECTOMY; HEARTBURN; HIP; HUMAN; JAPANESE; LUMBAR SPINE; MALE; OSTEOPOROSIS; PARTIAL GASTRECTOMY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; SPINE RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; BLOOD; BONE; BONE REMODELING; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; LONGITUDINAL STUDY; MIDDLE AGED; PATIENT; RADIOGRAPHY; SEXUAL DEVELOPMENT; STATISTICS; URINE;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COLLAGEN; FEMALE; GASTRECTOMY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT DROPOUTS; SEX CHARACTERISTICS; STATISTICS AS TOPIC;

EID: 77952498232     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-021-01209-2     Document Type: Erratum

References (25)

1. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, Auriola S, Chilton KM, Russell RG (1999) Molecular mechanism of action of bisphosphonate. Bone 24: 73S-79S
2. Iwamoto J, Takeda T, Sato Y (2006) Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 22:919-928
3. Iwamoto J, Takeda T, Sato Y (2007) Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis - usefulness of alendronate and risedronate. Expert Opin Pharmacother 8:2743-2756
4. Iwamoto J, Sato Y, Takeda T, Matsumoto H (2008) Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging 3:483-489
5. Lin JH, Chen IW, deLuna FA (1994) On the absorption of alendronate in rats. J Pharm Sci 83:1741-1746
6. Fliech H (2001) Bisphosphonates in bone disease from the laboratory to the patient, 4th edn. Academic Press, London, pp 64-71
7. Porras AG, Holland SD, Gertz BJ (1999) Pharmacokinetics of alendronate. Clin Pharmacokinet 36:15-28
8. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298
9. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139-150
10. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
11. Fukunaga M, Sone T (2003) Guideline for diagnosis and therapy of osteoporosis from a point of view of sex difference. Clin Calcium 13:1399-1404 (in Japanese)
12. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 10:183-192
13. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H (2002) The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 63:606-620
14. Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382-388
15. Tsuboi M, Nagamatsu S (1998) A comparison of dynamics of alendronate between elderly and non-elderly women. Shinryo-to-Shinyaku 1:43-49 (in Japanese)
16. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86:1212-1221
17. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M, Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society (2005) Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 23:97-104
18. Liedman B (1999) Symptoms after total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients - is reconstruction with a reservoir worthwhile? Nutrition 15:677-682
19. Lim JS, Kim SB, Bang HY, Cheon GJ, Lee JI (2007) High prevalence of osteoporosis in patients with gastric adenocarcinoma following gastrectomy. World J Gastroenterol 13:6492-6497
20. Iba K, Wada T, Takada J, Yamashita T (2003) Multiple insufficiency fractures with severe osteoporosis. J Orthop Sci 8:717-720
21. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-501
22. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302-329
23. Duques P, Araujo RSA, de Amorim WPD (2001) Esophagusenteric anastomosis ulceration caused by alendronate. Arq Gastroenterol 38:129-131
24. Tovey FI, Hall ML, Ell PJ, Hobsley M (1992) A review of postgastrectomy bone disease. J Gastroenterol Hepatol 7:639-645
25. Bisballe S, Buus S, Lund B, Hessov I (1986) Food intake and nutritional status after gastrectomy. Hum Nutr Clin Nutr 40:301-308